Porton Pharma Solutions Ltd. (SHE:300363)
China flag China · Delayed Price · Currency is CNY
21.14
+0.21 (1.00%)
Oct 28, 2026, 10:25 AM CST

Porton Pharma Solutions Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-95.7296.34-287.75266.862,005523.92
Depreciation & Amortization
416.02419.36401.49349.11259.67192.2
Other Amortization
56.7753.4344.3230.276.884.26
Loss (Gain) From Sale of Assets
1.171.170.77-0.54-0.13.21
Asset Writedown & Restructuring Costs
22.822.892.5758.1318.6316.22
Loss (Gain) From Sale of Investments
-6.52-6.5249.247.7628.186.79
Provision & Write-off of Bad Debts
18.2118.2120.28-35.2433.1243.47
Other Operating Activities
319.4142.2911.6923.12-50.74-1.13
Change in Accounts Receivable
-80.21-80.21-80.55954.72-330.48-736.71
Change in Inventory
-38.21-38.21-105.9130.04-163.58-315.56
Change in Accounts Payable
191.39191.39289.92-1,173732.54756.73
Operating Cash Flow
842.07757.01405.53629.062,564480.17
Operating Cash Flow Growth
56.73%86.67%-35.53%-75.47%434.06%-4.80%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-114.96-292.57-490.58-1,130-1,173-776.97
Sale of Property, Plant & Equipment
63.923.952.532.351.346.99
Cash Acquisitions
-----233.33-171.1
Investment in Securities
150.78-391.79-15-20-26.515.51
Other Investing Activities
0.852.563.132.76-4.659.4
Investing Cash Flow
100.59-677.84-499.95-1,115-1,436-916.17

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-220.41237.981,1191,345414.64
Long-Term Debt Repaid
--684.23-328.64-574.14-1,266-353.43
Lease Payments
-80.21-80.21-88.33-76.07-47.09-35.13
Total Debt Repaid
-707.62-684.23-328.64-574.14-1,266-353.43
Net Debt Issued (Repaid)
-497.56-463.82-90.66544.4378.1961.2
Issuance of Common Stock
10.72--1.2116.165.01
Repurchase of Common Stock
---9.87-19.39-100-
Common Dividends Paid
-66.91-30.11-301.5-626.57-129.08-82.76
Other Financing Activities
-106.99--11.71-28.22395.63306.76
Financing Cash Flow
-660.75-493.92-413.74-128.54260.84350.22

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-32.26-11.164.5155.2949.04-9.05
Net Cash Flow
249.65-425.91-503.66-558.951,438-94.83

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
727.11464.45-85.06-500.811,391-296.8
Free Cash Flow Growth
321.61%-----
Free Cash Flow Margin
19.98%13.58%-2.82%-13.66%19.78%-9.56%
Free Cash Flow Per Share
1.360.87-0.16-0.922.56-0.55
Levered Free Cash Flow
526.48237.56-158.53-1,174905.7-513.5
Unlevered Free Cash Flow
531.54269.11-119.74-1,146923.03-499.94
Free Cash Flow After Leases
646.9384.23-173.39-576.881,344-331.93

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
--1.34-67.1430.17-137.27-73.82
Change in Working Capital
109.93109.9372.91-70.41263.33-308.76